Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2021-12-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the pharmacokinetics and safety of inhaled vancomycin in patients with cystic fibrosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

NCT01093521

Cystic Fibrosis

COMPLETED PHASE1

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

NCT02504827

Cystic Fibrosis

COMPLETED PHASE4

Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis

NCT02694393

Cystic Fibrosis

TERMINATED PHASE1/PHASE2

Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis

NCT00570349

Cystic Fibrosis

COMPLETED PHASE1/PHASE2

Antimicrobial Resistance in Cystic Fibrosis (CF)

NCT00360503

Cystic Fibrosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection in patients with cystic fibrosis has increased dramatically over the last decade. Epidemiologic evidence suggests that persistent infection with MRSA may result in an increased rate of decline in FEV1 and shortened survival. Treatment of MRSA is a top priority. Inhaled antibiotics offer the advantage of high concentrations of antibiotic at the site of infection (the airway) while minimizing systemic side effects. Vancomycin is a glycopeptide antibiotic that has activity against MRSA. Anecdotal and retrospective peer-reviewed studies have demonstrated that inhaled vancomycin is safe and potentially effective in patients with cystic fibrosis and MRSA airway infection. Data evaluating the pharmacokinetics of vancomycin in sputum are needed before pursuing treatment trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis Methicillin-resistant Staphylococcus Aureus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vancomycin for Inhalation

250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Group Type EXPERIMENTAL

Vancomycin

Intervention Type DRUG

250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vancomycin

250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nebulized vancomycin Inhaled Vancomycin Vancomycin for inhalation Aerosolized Vancomycin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female ≥ 18 years of age.
* Confirmed diagnosis of CF based on the following criteria:

* positive sweat chloride \> 60 mEq/liter (by pilocarpine iontophoresis) and/or
* a genotype with two identifiable mutations consistent with CF or abnormal NPD, and
* one or more clinical features consistent with the CF phenotype.
* Chronic sputum producer able to spontaneously produce sputum
* FEV1 \> 40% of predicted normal for age, gender, and height
* Previous use of any inhaled antibiotics within the last year
* Ability to provide written informed consent
* Ability to adhere to the protocol

Exclusion Criteria

* Use of inhaled or intravenous vancomycin within two weeks of the study visit
* Known history of intolerance to inhaled vancomycin or inhaled albuterol.
* Known history of hypersensitivity to vancomycin or other glycopeptide antibiotics
* History of sputum culture with Burkholderia cepacia complex in the last two years.
* Pregnancy
* Woman who are lactating and not willing to stop nursing on the day of the study visit and the subsequent 48 hours.
* Current use of oral corticosteroids in doses exceeding the equivalent of 10mg of prednisone a day or 20mg of prednisone every other day.
* Patients not willing to hold other inhaled antibiotics (for example TOBI, Cayston, or Colistin) for at least 2 days prior to the study visit.
* Patients not willing to hold loop diuretics (i.e. furosemide, torsemide, ethacrynic acid) on the morning of the study visit.
* History of ABPA or reactive airways disease that has required treatment within the last year.
* Creatinine greater than 2.0 mg/dL within the last year.
* Oxygen saturation ≤ 92% on room air.
* History of patient reported hearing loss
* Any serious or active medical or psychiatric illness, which in the opinion of the investigator, would interfere with patient treatment, assessment, or adherence to the protocol.
* History of or listed for solid organ or hematological transplantation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No